Pheochromocytoma treatment agents

Pheochromocytoma treatment agents refer to a therapeutic grouping of medications specifically employed to manage the clinical manifestations and hemodynamic instability associated with catecholamine-secreting neuroendocrine tumors Rather than representing a single pharmacologic entity, this group primarily includes alpha-adrenergic receptor antagonists to counteract catecholamine-induced vasoconstriction, often supplemented by beta-adrenergic blockers to control reflex tachycardia, as well as ca...

Pheochromocytoma treatment agents refer to a therapeutic grouping of medications specifically employed to manage the clinical manifestations and hemodynamic instability associated with catecholamine-secreting neuroendocrine tumors

Rather than representing a single pharmacologic entity, this group primarily includes alpha-adrenergic receptor antagonists to counteract catecholamine-induced vasoconstriction, often supplemented by beta-adrenergic blockers to control reflex tachycardia, as well as catecholamine synthesis inhibitors like metyrosine that target tyrosine hydroxylase

Clinically, these agents are indicated for the preoperative stabilization of patients undergoing tumor resection, the acute control of paroxysmal hypertensive crises, and the long-term palliative management of inoperable or metastatic pheochromocytomas and functional paragangliomas

Clinically, these agents are indicated for the preoperative stabilization of patients undergoing tumor resection, the acute control of paroxysmal hypertensive crises, and the long-term palliative management of inoperable or metastatic pheochromocytomas and functional paragangliomas